Abstract
Introduction Cough is a hallmark symptom of multiple respiratory conditions. Technological advances have made it possible to monitor cough using smartphone applications continuously and objectively. However, these technologies have not yet been evaluated for their feasibility in real-world research conditions.
Methods We conducted 14-day continuous cough monitoring of presumptive TB patients enrolled as outpatients in a multi-center prospective tuberculosis diagnostics trial in Uganda, South Africa, Vietnam, the Philippines and India. Participants were given a smartphone with the Hyfe Research application installed, a carrier sling, and training on how to use both the phone and the cough application. We evaluated how often and how long participants recorded, and when coughs were detected. We also compared multiple cough frequency metrics for their performance in detecting changes in cough frequency.
Results Of 693 participants who consented to continuous cough monitoring for 14 days, 568 (82.0%) completed at least one recording session successfully. Among these 568 participants, 421 (74.1%) recorded on at least 10 of the 14 days in the recording period for a median of 23.9 hours per day. We detected coughs in a diurnal pattern with a median of 1 cough per hour detected between 6am and 2pm local time and a median of 0 coughs for all other hours. We found median coughs per hour to be the cough frequency metric most robust to outlier values while still detecting changes in cough frequency during the recording period. Implementation challenges include the visibility of cough monitoring devices, nighttime recording and concurrent charging of devices.
Conclusions Continuous cough monitoring using a smartphone application is feasible in low- and middle-income country settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Number 5U01AI152087. SH is supported by a Canadian Institute of Health Research Postdoctoral Fellowship, a UCSF Division of Pulmonary and Critical Medicine T32 Fellowship, and a UCSF Center for Tuberculosis and NIH/NIAID R25AI147375 award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was obtained from institutional review boards (IRB) in the US and in each study site. In the US, approval was obtained from the University of California San Francisco IRB (# 20-32670). In Vietnam, approval was obtained from the Ministry of Health Ethical Committee for National Biological Medical Research (94/CN-HĐĐĐ), the National Lung Hospital Ethical Committee for Biological Medical Research (566/2020/NCKH) and the Hanoi Department of Health, Hanoi Lung Hospital Science and Technology Initiative Committee (22/BVPHN). In India, approval was obtained from Christian Medical College IRB (13256). In South Africa, approval was obtained from Stellenbosch University Health Research Ethics Committee (17047). In Uganda, approval was obtained from Makerere University, College of Health Sciences, School of Medicine, Research Ethics Committee (2020-182). In the Philippines, approval was obtained from De La Salle Health Sciences Institute Independent Ethics Committee (2020-33-02-A).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
